Overactive Bladder Treatment Global Market Report 2024

The overactive bladder treatment market size has grown steadily in recent years. It will grow from $3.01 billion in 2023 to $3.13 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth observed during the historical period can be ascribed to advancements in medication, increased patient awareness, demographic changes, adherence to clinical guidelines, and substantial investments in research.

The overactive bladder treatment market size is expected to see steady growth in the next few years. It will grow to $3.7 billion in 2028 at a compound annual growth rate (CAGR) of 4.3%. The anticipated growth in the forecast period can be linked to factors such as an aging population, the development of advanced therapies, the implementation of personalized medicine, increased healthcare investments, and a focus on patient-centric care. Key trends expected during this period encompass non-pharmacological interventions, the adoption of digital health solutions, growing acceptance of alternative medicine, the incorporation of gender-specific approaches, and an emphasis on holistic care.

The overactive bladder treatment market is poised for growth, driven by the increasing elderly population. With the geriatric demographic, encompassing individuals aged 65 and older, being more susceptible to urinary tract infections due to factors such as diminished urine flow, overactive bladder, enlarged prostate, or kidney stones, there is a heightened demand for treatments targeting overactive bladder symptoms. As reported in July 2022 by ReliefWeb, the global population aged 65 and older is projected to rise from 10% in 2022 to 16% in 2050, reaching 94 million individuals, constituting 23% of the total population by 2050. Thus, the expanding geriatric population is a key factor propelling the overactive bladder treatment market's growth.

The prevalence of bladder cancer is another significant driver for the growth of the overactive bladder treatment market. Bladder cancer, characterized by abnormal cell growth in the bladder, often manifests with symptoms of overactive bladder. Treating these symptoms is crucial for improving the quality of life for individuals with bladder cancer. According to the American Society of Clinical Oncology's estimation in March 2023, around 82,290 adults in the United States are anticipated to be diagnosed with bladder cancer, with approximately 16,710 deaths expected in 2023. This underscores the correlation between bladder cancer and the prevalence of overactive bladder, contributing to the market's growth.

A notable trend in the overactive bladder treatment market is the approval of new products. Leading companies in the market are investing in the development of advanced products that incorporate the latest technologies to maintain their market positions. For example, in April 2023, Avation Medical Inc., a US-based company specializing in advanced neuromodulation and digital health, received FDA clearance for The Vivally System. This non-invasive bladder control therapy device, along with its accompanying mobile application, is designed to treat individuals suffering from urge urinary incontinence and urine urgency linked to overactive bladder syndrome. The system combines an ankle-worn garment with an intelligent controller, delivering personalized neuromodulation energy to the tibial nerve.

Innovation in treatments is a key focus for major companies in the overactive bladder treatment market. One such innovation involves the development of adrenergic receptor agonists, which mimic the effects of natural neurotransmitters to bind to adrenergic receptors. For instance, in April 2021, Urovant Sciences Ltd., a US-based clinical-stage biopharmaceutical company, introduced GEMTESA (vibegron) 75 mg tablets. This oral, once-daily medication is designed to address overactive bladder symptoms in adults, gaining approval from the U.S. Food and Drug Administration (FDA) as the first in its class for treating overactive bladder. Common side effects include dry mouth, headache, and constipation.

In March 2021, Sumitovant Biopharma, a US-based biopharmaceutical company, acquired Urovant Sciences Ltd. for an undisclosed amount. This strategic move is expected to provide long-term capital for business objectives and emphasize Sumitovant's commitment to developing and commercializing innovative therapies for urologic conditions, including overactive bladder treatments.

Major companies operating in the overactive bladder treatment market report are AbbVie Inc., Astellas Pharma Inc., Laborie Medical Technologies Corporation, Endo International plc, Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson Services Inc., Medtronic plc, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Limited, Cogentix Medical Inc., Dr. Reddy’s Laboratories Ltd., Sumitomo Pharma Co. Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Limited, Merck & Co. Inc., Macleods Pharmaceuticals Ltd., Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals Inc., Mesoblast Limited, Novartis International AG, Novo Nordisk A/S, Daiichi Sankyo Company ltd., Boston Scientific Corporation, Grünenthal GmbH, Mallinckrodt Pharmaceuticals, Collegium Pharmaceutical Inc.

North America was the largest region in the overactive bladder treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the overactive bladder treatment market report during the forecast period. The regions covered in the overactive bladder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the overactive bladder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of diseases in the treatment of overactive bladder are idiopathic bladder overactivity and neurogenic bladder overactivity. Idiopathic bladder overactivity involves an involuntary contraction of the bladder muscle, leading to a sudden and urgent urge to urinate. This condition is managed through overactive bladder (OAB) treatment methods, including anticholinergics and beta-3 agonists. Various therapies such as anticholinergics, mirabegron, neurostimulation, intravesical instillation, and other approaches are employed to treat these diseases. These therapies are available through channels such as hospital pharmacies, drug stores, retail pharmacies, and online providers.

The overactive bladder treatment market research report is one of a series of new reports that provides overactive bladder treatment market statistics, including overactive bladder treatment industry global market size, regional shares, competitors with an overactive bladder treatment market share, detailed overactive bladder treatment market segments, market trends and opportunities, and any further data you may need to thrive in the overactive bladder treatment industry. This overactive bladder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.